Literature DB >> 11334774

Pathophysiology of chronic heart failure.

G S Francis1.   

Abstract

Heart failure is a changing paradigm. The hemodynamic model, which served our needs well from the 1950s through the early 1980s, has now been largely abandoned, except for the management of decompensated patients in the hospital. The pathophysiology is exceedingly complex and involves structural changes, such as loss of myofilaments, apoptosis and disorganization of the cytoskeleton, as well as disturbances in Ca(2+) homeostasis, alteration in receptor density, signal transduction, and collagen synthesis. A more contemporary working hypothesis is that heart failure is a progressive disorder of left ventricular remodeling, usually resulting from an index event, that culminates in a clinical syndrome characterized by impaired cardiac function and circulatory congestion. This change in the framework of our understanding of the pathophysiology of heart failure is predicated on the results of numerous clinical trials conducted during the past 20 years. New therapies are now evolving that are designed to inhibit neuroendocrine and cytokine activation, whereas drugs specifically designed to heighten cardiac contractility and "unload" the left ventricle have proven to be unhelpful in long-term management of patients with chronic heart failure. However, the hemodynamic model is still relevant for patients in the hospital with decompensated heart failure, where positive inotropic drugs and vasodilators are still widely used. The modern treatment of chronic heart failure is now largely based on the neurohormonal hypothesis, which states that neuroendocrine activation is important in the progression of heart failure and that inhibition of neurohormones is likely to have long-term benefit with regard to morbidity and mortality. Thus, the evolution of treatment for chronic heart failure as a result of clinical trials has provided much enlightenment for our understanding of the fundamental biology of the disorder, a reversal of the usual flow of information from basic science to clinical investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334774     DOI: 10.1016/s0002-9343(98)00385-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  45 in total

Review 1.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 2.  Myocardial adaptations in the failing heart: cause or consequence?

Authors:  Sabine J van Dijk; Nazha Hamdani; Ger J M Stienen; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2009-02-14       Impact factor: 2.698

Review 3.  The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence.

Authors:  E Galli; A Pingitore; G Iervasi
Journal:  Heart Fail Rev       Date:  2008-12-27       Impact factor: 4.214

4.  Scan-rescan reproducibility of diastolic left ventricular kinetic energy, viscous energy loss and vorticity assessment using 4D flow MRI: analysis in healthy subjects.

Authors:  Vivian P Kamphuis; Jos J M Westenberg; Roel L F van der Palen; Pieter J van den Boogaard; Rob J van der Geest; Albert de Roos; Nico A Blom; Arno A W Roest; Mohammed S M Elbaz
Journal:  Int J Cardiovasc Imaging       Date:  2018-01-05       Impact factor: 2.357

Review 5.  Nutrient sensing and utilization: Getting to the heart of metabolic flexibility.

Authors:  Timothy M Griffin; Kenneth M Humphries; Michael Kinter; Hui-Ying Lim; Luke I Szweda
Journal:  Biochimie       Date:  2015-10-22       Impact factor: 4.079

Review 6.  Pharmacological treatment of chronic heart failure.

Authors:  Rachele Adorisio; Leonardo De Luca; Joseph Rossi; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

Review 7.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

8.  Chronic adrenaline treatment fails to down-regulate the Del301-303-alpha2B-adrenoceptor in neuronal cells.

Authors:  S Salim; A N Desai; M Taneja; D C Eikenburg
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

9.  Left ventricular remodeling after myocardial infarction: characterization of a swine model on beta-blocker therapy.

Authors:  Franca S Angeli; Mia Shapiro; Nicolas Amabile; Gina Orcino; Charles S Smith; Theresa Tacy; Andrew J Boyle; Kanu Chatterjee; Stanton A Glantz; William Grossman; Yerem Yeghiazarians
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

10.  Effects of Astragaloside IV on heart failure in rats.

Authors:  Zhuanyou Zhao; Weiting Wang; Fang Wang; Kerui Zhao; Yingmei Han; Weiren Xu; Lida Tang
Journal:  Chin Med       Date:  2009-04-02       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.